US4983387A
Expired / Lapsed
US
⏱️ 0.0 years remaining
HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
Assignee: Viral Technologies Inc
•
Filing: 1989-01-23
•
Granted: 1991-01-08
•
Expires: 2009-01-23
Abstract
Abstract Vaccines effective in the inhibition of infection caused by the family of retroviruses, HTLV-III, Human T-Cell Leukemia Virus, LAV, Lymphadenopathy-associated virus, ARV-2, AIDS-Related Virus, (AIDS and AIDS-Related Complex) have been developed from an antisera prepared against thymosin alpha 1 (T alpha 1), a thymic hormone, as well as from antisera to synthetic peptide fragments of T alpha 1 and antisera to synthetic peptide inclusive of amino acid positions 92-109 of the p17 gag core protein of HTLV-III, LAV and ARV-2. In this 18 amino acid primary sequence that is a 44 to 50% homology between the gag protein and T alpha 1. Immunoglobulin (IgG)- enriched preparations of the T alpha 1 antisera have enhanced activity in blocking viral replication. A diagnostic test capable of directly detecting the presence of HTLV-III, LAV, ARV-2 and related retroviruses associated with AIDS and ARC is also described.
Inventors
- 👤 Allan Goldstein
- 👤 Su-Sun Wang
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 08:35
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; C07K16/00; C07K16/08; C07K16/10; C07K16/112; C07K16/114; C07K16/1143; C07K16/18; C07K16/26; A; A61; A61K; A61K39/00; C07K2317/00; C07K2317/30; C07K2317/34; C12; C12N; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/16011; C12N2740/16211; C12N2740/16222; Y; Y10; Y10S; Y10S435/00; Y10S435/974; Y10S435/975; Y10S530/00; Y10S530/806; Y10S530/807; Y10S530/82; Y10S530/826; Y10S930/00; Y10S930/01; Y10S930/22; Y10S930/221
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
41 words
A peptide having the formula Ile-Y 1 -Y 2 -Lys-Asp-Thr-Lys-Glu-Ala-Leu-Y 3 -Lys-Ile-Glu-Glu-Glu-Gln-Asn wherein Y 1 is Asp or Glu, Y 2 is Val or Ile, and Y 3 is Glu or Asp, said peptide being capable of eliciting antibodies to HIV.
Claim 2
Dependent Claim
41 words
A peptide having the formula Ile-Y 1 -Y 2 -Lys-Asp-Thr-Lys-Glu-Ala-Leu-Y 3 -Lys-Ile-Glu-Glu-Glu-Gln-Asn wherein Y 1 is Asp or Glu, Y 2 is Val or Ile, and Y 3 is Glu or Asp, said peptide being capable of eliciting antibodies to HIV.
Claim 3
Dependent Claim
19 words
The peptide of claim 1 wherein Y 1 is Asp, Y 2 is Val and Y 3 is Glu.
Claim 4
Dependent Claim
19 words
The peptide of claim 1 wherein Y 1 is Glu, Y 2 is Ile and Y 3 is Asp.
Claim 5
Dependent Claim
217 words
A peptide fragment of HIV p17 gag protein containing from 18 up to no more than about 38 amino acids and having the formula (II): A-Ile-Y.sub.1 -Y.sub.2 -Lys-Asp-Thr-Lys-Glu-Ala-Leu-Y.sub.3 -Lys Ile-Glu-Glu-Glu-Gln-Asn-B (II) wherein Y 1 is Asp or Glu, Y 2 is Val or Ile, and Y 3 is Glu or Asp, A is H or an amino acid sequence of 1 up to about 10 amino acids, said amino acid sequence being selected from the group consisting of the amino acid at position 91 and amino acid sequences between positions 90 and 91, 89 and 91, 88 and 91, 87 and 91, 86 and 91, 84 and 91, 85 and 91, 84 and 91, 83 and 91, and 82 and 91 of the p17 gag protein of HIV virus; and B is OH or an amino acid sequence of 1 up to about 10 amino acids, said amino acid sequence being selected from the group consisting of the amino acid at position 110 and the amino acid sequences between positions 110 and 111, 110 and 112, 110 and 113, 110 and 114, 110 and 115, 110 and 116, 110 and 117, 110 and 118, and 110 and 119 of the p17 gag protein of HIV virus, said peptide having the ability to raise antibodies recognizing HIV virus.
Claim 6
Dependent Claim
217 words
A peptide fragment of HIV p17 gag protein containing from 18 up to no more than about 38 amino acids and having the formula (II): A-Ile-Y.sub.1 -Y.sub.2 -Lys-Asp-Thr-Lys-Glu-Ala-Leu-Y.sub.3 -Lys Ile-Glu-Glu-Glu-Gln-Asn-B (II) wherein Y 1 is Asp or Glu, Y 2 is Val or Ile, and Y 3 is Glu or Asp, A is H or an amino acid sequence of 1 up to about 10 amino acids, said amino acid sequence being selected from the group consisting of the amino acid at position 91 and amino acid sequences between positions 90 and 91, 89 and 91, 88 and 91, 87 and 91, 86 and 91, 84 and 91, 85 and 91, 84 and 91, 83 and 91, and 82 and 91 of the p17 gag protein of HIV virus; and B is OH or an amino acid sequence of 1 up to about 10 amino acids, said amino acid sequence being selected from the group consisting of the amino acid at position 110 and the amino acid sequences between positions 110 and 111, 110 and 112, 110 and 113, 110 and 114, 110 and 115, 110 and 116, 110 and 117, 110 and 118, and 110 and 119 of the p17 gag protein of HIV virus, said peptide having the ability to raise antibodies recognizing HIV virus.
Claim 7
Dependent Claim
69 words
The peptide of claim 7 having the formula (II)-1: A.sup.1 -Ile-Y.sub.1 -Y.sub.2 -Lys-Asp-Thr-Lys-Glu-Ala-Leu-Y.sub.3 -Lys-Ile-Glu-Glu-Glu-Gln-Asn-B.sup.1 (II)- 1 where Y 1 , Y 2 and Y 3 are as defined: A 1 is a member selected from the group consisting of HH, Arg, Gln-Arg, His-Gln-Arg, Val-His-Gln-Arg, Ser-Val-His-Gln-Arg, Cys-Val-His-Gln-Arg, Tyr-Ser-Val-His-Gln-Arg, and Tyr-Cys-Val-His-Gln-Arg, and B 1 is a member selected from the group consisting of H, Lys, Lys-Ser, Lys-Ser-Lys, Lys-Ser-Lys-Lys, Lys-Ser-Lys-Lys-Lys, and Lys-Ser-Lys-Lys-Lys-Ala.
Claim 8
Dependent Claim
19 words
The peptide of claim 5 wherein Y 1 is Asp, Y 2 is Val and Y 3 is Glu.
Claim 9
Dependent Claim
19 words
The peptide of claim 5 wherein Y 1 is Glu, Y 2 is Ile and Y 3 is Asp.
Claim 10
Dependent Claim
48 words
The peptide of claim 5 which is a triacontapeptide fragment of HIV at positions 86-115 of the p17 gag protein or the [Ser] 87 analog thereof having the formula Tyr-A 1 -Val-His-Gln-Arg-Ile-Asp-Val-Lys-Asp-Thr-Lys-Glu-Ala-Leu-A 2 -Lys-Ile-Glu-Glu-Glu-Gln-Asn-Lys-Ser-Lys-Lys-Lys-Ala, where A 1 is Cys or Ser and A 2 is Asp or Glu.
Claim 11
Dependent Claim
10 words
The triacontapeptide of claim 8 where A 1 is Cys.
Claim 12
Dependent Claim
15 words
The triacontapeptide of claim 8 where A 1 is Ser and A 2 is Glu.
Claim 13
Dependent Claim
16 words
An immunogenic antigen comprising the peptide of claim 4 covalently bonded to an immunogenic carrier material.
Claim 14
Dependent Claim
40 words
The antigen of claim 11 wherein the immunogenic carrier material is a member selected from the group consisting of albumins, globulins, thyroglobulins, hemoglobulins, hemocyanins, ascaris protein extract, polylysine, polyglutamic acid, copolymers of lysine or ormithine; diphtheria toxoid and tetanus toxoid.
Claim 15
Dependent Claim
14 words
The antigen of claim 11 wherein the immunogenic carrier material is Keyhole limpet hemocyanin.
Claim 16
Dependent Claim
16 words
The antigen of claim 11 wherein the immunogenic carrier material is diphtheria toxoid or tetanus toxoid.
Claim 17
Dependent Claim
16 words
An immunogenic antigen comprising the peptide of claim 1 covalently bonded to an immunogenic carrier material.
Claim 18
Dependent Claim
16 words
An immunogenic antigen comprising the peptide of claim 5 covalently bonded to an immunogenic carrier material.
Claim 19
Dependent Claim
16 words
An immunogenic antigen comprising the peptide of claim 8 covalently bonded to an immunogenic carrier material.
References Cited (Backward Citations)
US4079127A
Cited
US4116951A
Cited
US4148788A
Cited
US4353821A
Cited
US4470926A
Cited
US4612365A
Cited
US4339427A
Cited
US4504415A
Cited
US4614731A
Cited
WO1986001827A1
Cited
GB2181435A
Cited
EP0230222A1
Cited
US4735896A
Cited
US4863730A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-01-07 | 1994-07-09 | 1995-01-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-01-07 | 1998-07-09 | 1999-01-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-01-07 | 2002-07-09 | 2003-01-08 | $7700.00 | Window Closed / Lapsed |